Search results
Showing 466 to 480 of 667 results for diabetes
Intravenous fluid therapy in children and young people in hospital (NG29)
This guideline covers general principles for managing intravenous (IV) fluids for children and young people under 16 years, including assessing fluid and electrolyte status and prescribing IV fluid therapy. It applies to a range of conditions and different settings. It does not include recommendations relating to specific conditions. This guideline represents a major opportunity to improve patient safety for children and young people having IV fluid therapy in hospital.
This evidence summary has been updated and replaced by NICE advice ESNM26.
This evidence summary has been updated and replaced by NICE guideline NG28.
This evidence summary has been updated and replaced by NICE guideline NG28.
This evidence summary has been replaced by NICE technology appraisal guidance 336.
This evidence summary has been updated and replaced by NICE guideline NG28.
This guidance has been replaced by NICE technology appraisal guidance 63 [Replaced by NICE guideline CG66].
This guidance has been replaced by NICE technology appraisal guidance 63.
This indicator has been updated and replaced by NICE indicator 300 and NICE indicator 301.
This indicator has been updated and replaced by NICE indicator 298 and NICE indicator 299.
This guideline covers diagnosing and managing abdominal aortic aneurysms. It aims to improve care by helping people who are at risk to get tested, specifying how often to monitor asymptomatic aneurysms, and identifying when aneurysm repair is needed and which procedure will work best.
This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.
Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making
Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)
Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir or Symmetrel) or zanamivir (Relenza) to prevent influenza (flu).
Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)
Evidence-based recommendations on amantadine (Lysovir), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza in children and adults.